Quintrio
Home

PHARMACEUTICAL PREPARATIONS

BioVie, Inc. Common Stock

BIVI

BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.

Last trade $0.9756
Day change -$0.1044 (-9.67%)
Day range $0.974 – $1.14
Volume 383,315
Market cap $12M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$11.58M
Price / earnings
—
Price / book
1.77×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.17×

Profitability

Earnings per share
-$2.11
Return on assets
-204.66%
Return on equity
-346.02%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
2.4×
Quick ratio
2.4×
Cash ratio
1.78×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$18.91M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for BIVI, quarterly periods
Line itemQ1 FY2027 Sep 30, 2026Q4 FY2026 Jun 30, 2026Q3 FY2026 Mar 31, 2026Q2 FY2026 Dec 31, 2025Q1 FY2026 Sep 30, 2025Q4 FY2025 Jun 30, 2025Q3 FY2025 Mar 31, 2025Q2 FY2025 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$2.31M$2.13M$2.15M$1.94M$2.29M$2.38M$1.59M$2.53M
Research and development$3.34M$3.58M$3.18M$4.27M$2.94M$1.22M$1.34M$4.7M
Total operating expenses$5.65M$5.72M$5.39M$6.26M$5.28M$3.66M$2.99M$7.29M
Operating income-$5.65M-$5.72M-$5.39M-$6.26M-$5.28M-$3.66M-$2.99M-$7.29M
Interest expense-$968-$3.98K-$5.97K-$5.97K-$1.99K-$5K-$5K-$66.7K
Income before taxes-$5.61M-$5.65M-$5.27M-$6.07M-$5.09M-$3.49M-$2.79M-$7.11M
Income taxes$0$0$0$0$0$0$0$0
Net income-$5.61M-$5.65M-$5.27M-$6.07M-$5.09M-$3.49M-$2.79M-$7.11M
Net income attributable to common shareholders-$5.61M-$5.65M-$5.27M-$6.07M-$5.13M-$3.49M-$2.79M-$7.16M
EBITDA-$5.65M-$5.71M-$5.33M-$6.2M-$5.23M-$3.61M-$2.93M-$7.24M
Basic earnings per share-$0.68-$0.68-$0.70-$0.77-$0.98-$1.89-$1.51-$4.55
Diluted earnings per share-$0.68-$0.68-$0.70-$0.77-$0.98-$1.89-$1.51-$4.55

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

BioVie to Host Live Investor Webinar and Q&A on Oct. 8

BioVie Inc. will host an investor webinar discussing its drug therapies for neurological diseases, focusing on bezisterim for Alzheimer's, Parkinson's, and long COVID, and BIV201 for liver cirrhosis complications.

Benzinga

BioVie Inc. Announces Pricing of $12 Million Public Offering

BioVie Inc. has priced a public offering of 6 million units at $2.00 per unit, expecting to raise approximately $12 million. The offering includes common stock and warrants, with proceeds intended for working capital and general corporate purposes.

GlobeNewswire Inc.

BioVie Inc. Announces Pricing of $12 Million Public Offering

BioVie Inc. is pricing a public offering of 6 million units, each consisting of one common stock share and one warrant, expected to raise approximately $12 million for working capital and general corporate purposes.

GlobeNewswire Inc.

BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology

BioVie presented research showing its drug Bezisterim potentially reduces biological age in Alzheimer's patients by modulating DNA methylation across multiple biological clocks, with significant improvements in inflammatory and metabolic biomarkers.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jul 7, 20251-for-10reverse split
Aug 6, 20241-for-10reverse split
Nov 22, 20191-for-125reverse split